Distreptaza suppositories pharmachologic effect:
As part of the preparation two active components: streptokinase and streptodornase. Streptokinase refers to the fibrinolytic enzyme, promoting the conversion of inactive plasminogen into active plasmin which dissolves fibrin fibers in clot. Streptodornase - an enzyme that is capable of dissolving pus and dead cells, without causing an impact on healthy cells and their function. Effect of the drug is to facilitate the access of antibiotics to the site of inflammation.
Indications:
Treatment of acute and chronic adnexitis, salpingitis, endometritis, post-surgical infiltrates, acute and chronic inflammation of hemorrhoidal veins paraproctitis and fistulas, cysts of the coccyx, after operations on the abdominal and pelvic cavity to prevent adhesions.
Distreptaza suppositories mode of application:
Candles are administered rectally, most deeply. The dose depends on the severity of inflammation.
Severe: 1 suppository 3 times / day for 3 days on 1 suppository 2p / day 3 days, then 1 suppository 1p / day for 3 days.
Medium and light severity: 1 suppository 2 times / day 3days, then on 1 candle 1p / day for 4 days, or 2 p / day for 2 days. The course of treatment is generally from 7 to 10 days and involves the use of 8 to 18 suppoziroriev.
Distreptaza suppositories side effects:
There may be an allergy, pyrexia, increased risk of bleeding.
Contraindications:
Action Distreptaza should not extend to the area of fresh wounds and post-surgical sutures because of the risk of bleeding. Pregnancy and lactation.
Distreptaza suppositories during pregnancy:
Use is contraindicated.
Interaction with other drugs:
Potentiates the effect of antibiotics, chemotherapy drugs by accelerating their introduction into the inflammatory focus.
Product:
Rectal suppositories creamy white mass 2 g ± 0,1 g
Storage conditions:
Store in a cool place at 2-8 degrees Celsius. Do not freeze.
Composition:
1 suppository contains 15,000 IU streptokinase, streptodornase 1250 IU.
Other ingredients: paraffin oil, Witepsol H15.
Pharmacological group:
Drugs affecting mainly the processes of tissue metabolism
Medicines affecting coagulation
Drugs that inhibit blood coagulation
Fibrinolytic drugs
Additionally:
There is no experience on the use of the drug in children.
New
New
New
New
New
New
